[Acute lymphoblastic leukemia in developing countries: Management from the transplant indication (allo/auto) until post-transplant follow-up. Guidelines from the SFGM-TC].

{"article_title":"[Acute lymphoblastic leukemia in developing countries: Management from the transplant indication (allo\/auto) until post-transplant follow-up. Guidelines from the SFGM-TC].","author":"Yafour N, Hamzy F, Elkababri M, Yakoub-Agha I, Bekadja MA","journal_title":"Bulletin du cancer","issn":"1769-6917","isbn":"","publication_date":"2023-02-01","volume":"110","issue":"2S","first_page":"S30","page_count":"","accession_number":"35562231","doi":"10.1016\/j.bulcan.2022.02.011","publisher":"Elsevier","doctype":"English Abstract","subjects":"Hematopoietic Stem Cell Transplantation; Precursor Cell Lymphoblastic Leukemia-Lymphoma therapy; Humans; Developing Countries; Follow-Up Studies; Bone Marrow Transplantation","interest_area":["Oncology"],"abstract":"Management of acute lymphoblastic leukemia (ALL) patients in countries with limited resources depends on the means of prognostic stratification, available treatment and logistics. During the 12th annual harmonization workshops of the francophone Society of bone marrow transplantation and cellular therapy (SFGM-TC), a designated working group reviewed the literature in order to elaborate unified guidelines for allogeneic hematopoietic cell transplantation (Allo-HCT) in this disease. Conventional poor prognostic factors can be used to determine the indication of allo-HCT in first remission. Patients lacking a HLA-matched related donor can be allografted with a haploidentical donor allo-HCT if available. Chemotherapy based conditioning regimen can be used if TBI is not available, because the probability to find a radiotherapy department with the capacity for total body irradiation is low. For patients with Philadelphia chromosome positive (Phi+) ALL, post-transplantation tyrosine kinase inhibitors as a systematic maintenance strategy is recommended. Autologous HCT is optional for Phi+ ALL patients with negative minimal residual disease, who not eligible for allo-HCT. Patients with refractory\/relapsed disease have a poor prognosis which highlights the importance of acquiring in the future new therapies such as: blinatumumab, inotuzumab, and CAR-T cells. Copyright \u00a9 2022 Soci\u00e9t\u00e9 Fran\u00e7aise du Cancer. Published by Elsevier Masson SAS. All rights reserved.","url":"https:\/\/search.ebscohost.com\/login.aspx?direct=true&db=mdl&AN=35562231","isPdfLink":false,"isSAML":false,"an":"35562231","number_other":"","type_pub":"","issn_electronic":"1769-6917","languages":"French","language":"fre","date_entry":"Date Created: 20220513 Date Completed: 20230217 Latest Revision: 20231129","date_update":"20240105","titleSource":"Bulletin du cancer [Bull Cancer] 2023 Feb; Vol. 110 (2S), pp. S30-S38. Date of Electronic Publication: 2022 May 11.","date_pub_cy":"","type_document":"","contract_publisher":"","authored_on":"2023-02-01","description":"Management of acute lymphoblastic leukemia (ALL) patients in countries with limited resources depends on the means of prognostic stratification, available treatment and logistics. During the 12th annual harmonization workshops of the francophone Society of bone marrow transplantation and cellular therapy (SFGM-TC), a designated working group reviewed the literature in order to elaborate unified guidelines for allogeneic hematopoietic cell transplantation (Allo-HCT) in this disease. Conventional poor prognostic factors can be used to determine the indication of allo-HCT in first remission. Patients lacking a HLA-matched related donor can be allografted with a haploidentical donor allo-HCT if available. Chemotherapy based conditioning regimen can be used if TBI is not available, because the probability to find a radiotherapy department with the capacity for total body irradiation is low. For patients with Philadelphia chromosome positive (Phi+) ALL, post-transplantation tyrosine kinase inhibitors as a systematic maintenance strategy is recommended. Autologous HCT is optional for Phi+ ALL patients with negative minimal residual disease, who not eligible for allo-HCT. Patients with refractory\/relapsed disease have a poor prognosis which highlights the importance of acquiring in the future new therapies such as: blinatumumab, inotuzumab, and CAR-T cells.<br \/> (Copyright © 2022 Société Française du Cancer. Published by Elsevier Masson SAS. All rights reserved.)","upload_link":"https:\/\/search.ebscohost.com\/login.aspx?direct=true&site=eds-live&scope=site&db=mdl&AN=35562231&authtype=shib&custid=ns346513&group=main&profile=eds","no_of_pages":"","authored_by":"Yafour N, Hamzy F, Elkababri M, Yakoub-Agha I, Bekadja MA"}